Serotonin Receptor Blockers in Ischemic Mitral Regurgitation
ConditionIschemic Mitral Regurgitation
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorLaval University
About this trial
This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.
Eligibility criteria
Qualifiers
Patients 18-80 years old with a 1st episode of STEMI with documented coronary obstruction.
Left ventricle ejection fraction (LVEF)<50% and mitral tenting area ≥ 4 cm2, OR LVEF ≤ 40% and inferior/posterior wall motion anomaly, OR LVEF≤30% and wall motion in any territory.
Disqualifiers
Inability to provide informed consent
Hemodynamic instability / cardiogenic shock / papillary muscle rupture
Prior mitral valve procedure/surgery
Permanent atrial fibrillation (limiting imaging and MR quantification)
Trial design
Treatments tested in this trial
- Cyproheptadine 4 Mg Oral Tablet
- Placebo
Treatment groups
214 Participants
are divided into 2 treatment groupsSponsors and collaborators
Laval University
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Source ClinicalTrials.gov